Geoffrey Chong

1.7k total citations
59 papers, 769 citations indexed

About

Geoffrey Chong is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Geoffrey Chong has authored 59 papers receiving a total of 769 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pathology and Forensic Medicine, 27 papers in Oncology and 16 papers in Genetics. Recurrent topics in Geoffrey Chong's work include Lymphoma Diagnosis and Treatment (30 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Colorectal Cancer Treatments and Studies (10 papers). Geoffrey Chong is often cited by papers focused on Lymphoma Diagnosis and Treatment (30 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Colorectal Cancer Treatments and Studies (10 papers). Geoffrey Chong collaborates with scholars based in Australia, United Kingdom and United States. Geoffrey Chong's co-authors include Eliza A. Hawkes, Andrew Grigg, David Cunningham, Graham Byrnes, Jeff Szer, David Watkins, A. Norman, Joel Wight, Bhawna Sirohi and Robert L. Campbell and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Geoffrey Chong

50 papers receiving 758 citations

Peers

Countries citing papers authored by Geoffrey Chong

Since Specialization

Citations

This map shows the geographic impact of Geoffrey Chong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geoffrey Chong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geoffrey Chong more than expected).

Fields of papers citing papers by Geoffrey Chong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geoffrey Chong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geoffrey Chong. The network helps show where Geoffrey Chong may publish in the future.

Co-authorship network of co-authors of Geoffrey Chong

This figure shows the co-authorship network connecting the top 25 collaborators of Geoffrey Chong. A scholar is included among the top collaborators of Geoffrey Chong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geoffrey Chong. Geoffrey Chong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Incidence of Venous Thromboembolism and Its Associated Risk Factors in Newly Diagnosed Multiple Myeloma Patients in the Klang Valley, Malaysia 2025 ·Journal of Clinical Medicine ·Noor Azah Abd Aziz, Sivakumar Palaniappan, (unknown), Geoffrey Chong, (unknown), Azimatun Noor Aizuddin, (unknown)	1
2	Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study 2025 ·Blood Advances ·Allison Barraclough, Sze Ting Lee, Melinda Burgess, Leonid Churilov, Geoffrey Chong, (unknown), Michael Gilbertson, (unknown), (unknown), David Ritchie, Rachel Koldej, Andrew M. Scott, Colm Keane, Eliza A. Hawkes	0
3	T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial 2025 ·Blood Advances ·Eliza A. Hawkes, Jodie Palmer, Richard Khor, (unknown), Melinda Burgess, Soi Cheng Law, Maher K. Gandhi, Geoffrey Chong, Jake Shortt, Rakin Chowdhury, (unknown), Leonid Churilov, Michael MacManus, Charmaine Smith, Fiona E. Scott, (unknown), Allison Barraclough, (unknown), Andrew M. Scott, Colm Keane	0
4	Factors associated with thrombosis among solid organ cancer patients in Kuala Lumpur, Malaysia 2025 ·Thrombosis Journal ·(unknown), Ibtisam Muhamad Nor, Fuad Ismail, Sivakumar Palaniappan, Geoffrey Chong, Sharifa Ezat Wan Puteh, (unknown), (unknown)	1
5	Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review 2025 ·Blood Advances ·(unknown), (unknown), Cameron Wellard, Allison Barraclough, Belinda A. Campbell, Geoffrey Chong, (unknown), Gareth P. Gregory, Greg Hapgood, Anna Johnston, Constantine S. Tam, Stephen Opat, Erica M. Wood, Zoe McQuilten, Eliza A. Hawkes	0
6	First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO study. 2024 ·Journal of Clinical Oncology ·Geoffrey Chong, Denise Lee, (unknown), Anneke Grobler, Richard Khor, Belinda A. Campbell, (unknown), (unknown), (unknown), (unknown), Colm Keane, Jodie Palmer, Eliza A. Hawkes	1
7	Underweight Body Mass Index Is an Independent Risk Factor for Overall Survival in Diffuse Large B-Cell Lymphoma Treated with Rituximab, Prednisolone, Cyclophosphamide, Vincristine, and Doxorubicin: A Lymphoma and Related Diseases Registry Study 2024 ·Blood ·(unknown), Şana Sungur, Cameron Wellard, (unknown), Susan Morgan, Denise Lee, Geoffrey Chong, Chan Y. Cheah, Eliza A. Hawkes, Erica M. Wood, Nada Hamad, Anna Johnston, (unknown)	0
8	First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab +/- nivolumab: An umbrella randomised phase 2 investigator-led study. 2024 ·Journal of Clinical Oncology ·Geoffrey Chong, Jodie Palmer, Allison Barraclough, Leonid Churilov, Colm Keane, Sze Ting Lee, Denise Lee, (unknown), Charmaine Smith, Eliza A. Hawkes	2
9	Utility of FDG-PET in predicting the histology of relapsed or refractory lymphoma 2023 ·Blood Advances ·(unknown), (unknown), Edward R. Scheffer Cliff, (unknown), Jiwoo Lee, Eliza A. Hawkes, Geoffrey Chong	4
10	Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study 2023 ·Leukemia ·(unknown), Geoffrey Chong, Colm Keane, Sze-Ting Lee, Charmaine Smith, Leonid Churilov, Joseph McKendrick, William Renwick, Piers Blombery, Melinda Burgess, (unknown), (unknown), (unknown), (unknown), Andrew M. Scott, Allison Barraclough, Joel Wight, Andrew Grigg, Chun Yew Fong, Eliza A. Hawkes	11
11	Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study 2021 ·Clinical Cancer Research ·Jennifer Mooi, Fiona Chionh, Peter Savas, Jessica Da Gama Duarte, Geoffrey Chong, Stephen Brown, Rachel Wong, Timothy Price, (unknown), Effie Skrinos, John M. Mariadason, Niall C. Tebbutt	12
12	435P The AGITG Modulate study: Randomised phase II study testing manipulation of the tumour micro environment (TME) to enable synergy with PD1 inhibitors in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) 2021 ·Annals of Oncology ·Niall C. Tebbutt, Matthew Burge, Craig Underhill, (unknown), (unknown), Adnan Nagrial, Nick Pavlakis, A.D. Strickland, Geoffrey Chong, Jeanne Tie, Rachel Wong, Timothy Price	1
13	Use of Ultrasonography Facilitates Noninvasive Evaluation of Lymphadenopathy in a Lymph Node Diagnostic Clinic 2020 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Eliza A. Hawkes, Fiona Chionh, Arun Azad, Geoffrey Chong	5
14	Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma 2020 ·Leukemia ·Georg Lenz, Eliza A. Hawkes, Gregor Verhoef, Corinne Haïoun, Soon Thye Lim, Dae Seog Heo, Kirit M. Ardeshna, Geoffrey Chong, Jacob Haaber, Wei Shi, Igor Gorbatchevsky, Susanne Lippert, Florian Hiemeyer, Paolo Piraino, Georg Beckmann, Carol E. Peña, (unknown), Barrett H. Childs, Gilles Salles	52
15	Bilateral papilledema on sunitinib therapy for advanced renal cell carcinoma 2010 ·Medical Oncology ·Jaclyn Yoong, Geoffrey Chong, Kate Hamilton	4
16	Longitudinal Assessment of Quality of Life in Rectal Cancer Patients With or Without Stomas Following Primary Resection 2009 ·Diseases of the Colon & Rectum ·Thomas Yau, David Watkins, David Cunningham, Yolanda Barbáchano, Ian Chau, Geoffrey Chong	52
17	A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy 2008 ·Cancer Chemotherapy and Pharmacology ·Alexandra Léary, L. Assersohn, David Cunningham, A. Norman, Geoffrey Chong, Gina Brown, Paul J. Ross, (unknown), (unknown), J. Oates	24
18	The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma 2006 ·Annals of Oncology ·Hendrik‐Tobias Arkenau, Geoffrey Chong, David Cunningham, David Watkins, (unknown), Bhawna Sirohi, (unknown), A. Norman, Andrew Wotherspoon, Alan Horwich	63
19	Oesophageal cancer: preoperative chemotherapy 2004 ·Annals of Oncology ·Geoffrey Chong, David Cunningham	6
20	Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy 2000 ·Bone Marrow Transplantation ·Geoffrey Chong, Graham Byrnes, Jeff Szer, Andrew Grigg	74

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact